{"created":"2023-06-19T10:30:54.679395+00:00","id":3062,"links":{},"metadata":{"_buckets":{"deposit":"0177f587-aa15-4eaf-a75a-a355a7e158fe"},"_deposit":{"created_by":3,"id":"3062","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"3062"},"status":"published"},"_oai":{"id":"oai:kwmed.repo.nii.ac.jp:00003062","sets":["1709617079800:37:807"]},"author_link":["131776","131772","131771","131775","131777","131773","131779","131774","131778","131780"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2022","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"151","bibliographicPageStart":"141","bibliographicVolumeNumber":"48","bibliographic_titles":[{},{"bibliographic_title":"Kawasaki medical journal","bibliographic_titleLang":"en"}]}]},"item_10001_description_34":{"attribute_name":"記事種別(英)","attribute_value_mlt":[{"subitem_description":"Regular Article","subitem_description_type":"Other"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Kawasaki Medical Society"}]},"item_10001_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.11482/KMJ-E202248141","subitem_relation_type_select":"DOI"}}]},"item_10001_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_name":[{}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://igakkai.kms-igakkai.com/wp/wp-content/uploads/2022en/KMJ-E202248141.pdf","subitem_relation_type_select":"URI"}}]},"item_10001_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA12029005","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"24343404","subitem_source_identifier_type":"ISSN"}]},"item_10001_text_32":{"attribute_name":"著者所属(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Department of Urology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Urology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Faculty of Science and Engineering, Tokyo Denki University"},{"subitem_text_language":"en","subitem_text_value":"Department of Urology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Urology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Urology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Urology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Urology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Director of Hospital, Kawasaki Medical School Hospital"},{"subitem_text_language":"en","subitem_text_value":"Department of Urology, Kawasaki Medical School"}]},"item_10001_textarea_5":{"attribute_name":"抄録(英)","attribute_value_mlt":[{"subitem_textarea_language":"en","subitem_textarea_value":"　Introduction and Objectives: Bacterial infections are the main cause of acute prostatitis and are treated with appropriate antimicrobial therapy. However, approximately 5% of patients continue to have inflammatory symptoms even after receiving antibacterial therapy, leading to refractory conditions. Bacterial prostatitis requires additional therapy, focusing on inflammatory changes. Indoleamine 2,3-dioxygenase 1 (IDO1) catalysis is the first rate-limiting step of tryptophan metabolism. IDO1 is expressed in the prostate and plays a key role in the immune response. As the first step in investigating the relationship between acute prostatitis and IDO1, we investigated the preventive effect of IDO1 inhibition on lipopolysaccharide (LPS)- induced prostatitis using IDO knockout (Ido1 −/−) mice in this study.\n　Materials and Methods: The study used Ido1 −/− and wild-type (Ido1 +/+) C57BL/6J male\nmice aged 10–15 weeks. LPS Escherichia coli O26 (100μg/PBS, 100μL) was administered transurethrally into the lower urinary tract to create a mouse model of LPS-induced prostatitis. The prostates were removed 1, 3, 5, and 7 days after creating the model mice. Histological, immunohistochemical, and biochemical analyses were used to compare the preventive effect in Ido1 −/− mice compared with that in Ido1+/+ mice.\n　Results: HE staining showed suppression of ductal destruction following infiltration of inflammatory cells in Ido1 −/− mice compared with Ido1 +/+ mice. The enzyme-linked immunosorbent assay (ELISA) method was used for kynurenine pathway analysis, which showed significantly maintained tryptophan levels and decreased L-kynurenine levels in Ido1 −/− mice compared to Ido1 +/+ mice. The IDO1 assay in Ido1 +/+ mice showed significantly increased levels during all observation periods after creating the model compared with that under normal conditions. Immunofluorescent staining using five types of cytokines and chemokines (IL-2, IL-4, IL-17, CCL2, and CCL3) related to the pathophysiology of acute prostatitis showed decreased expression of these cytokines and chemokines in Ido1 -/- mice compared with Ido1 +/+ mice. Inflammation-related proteome assays showed decreased levels of IL-1β, IL-4, IL-5, IL-6, IL-17, CCL2, CCL3, CXCL1, CXCL11, and tissue inhibitor of matrix metalloproteinases (TIMP)-1 in Ido1 −/− mice compared with Ido1 −/− mice during all observation periods after model creation.\n　Conclusions: IDO1 is involved in LPS-induced prostatitis through cytokines and chemokines. IDO1 inhibition contributes to the prevention of LPS-induced prostatitis. IDO1 inhibition has the potential to serve as an additional therapy for acute prostatitis.\n\n"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"TAKASAKI, Hiroyasu","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"OHIRA, Shin","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"TONE, Shigenobu","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KAKUMAE, Sho","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"NAKATSUKA, Tota","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"MORINAKA, Hirofumi","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"HIRATA, Keita","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"SHIMIZU, Shinjiro","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"NAGAI, Atsushi","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"UEHARA, Shinya \\n","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2023-03-10"}],"displaytype":"detail","filename":"KMJ-E202248141.pdf","filesize":[{"value":"4.8 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"PDF","url":"https://kwmed.repo.nii.ac.jp/record/3062/files/KMJ-E202248141.pdf"},"version_id":"560fc41a-f432-4249-b5d4-c7d1e809db1e"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Indoleamine 2,3-dioxygenase 1","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Prostatitis","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Prevention","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Anti-inflammation","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"lipopolysaccharide","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Preventive effect of indoleamine 2,3-dioxygenase 1 inhibition on lipopolysaccharide-induced prostatitis","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Preventive effect of indoleamine 2,3-dioxygenase 1 inhibition on lipopolysaccharide-induced prostatitis","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"3","path":["807"],"pubdate":{"attribute_name":"公開日","attribute_value":"2023-03-10"},"publish_date":"2023-03-10","publish_status":"0","recid":"3062","relation_version_is_last":true,"title":["Preventive effect of indoleamine 2,3-dioxygenase 1 inhibition on lipopolysaccharide-induced prostatitis"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-06-19T10:48:16.034489+00:00"}